Literature DB >> 30177238

[Survival in HIV-1 patients receiving antiretroviral therapy in Morocco].

H Titou1, N Baba2, J Kasouati3, S Oumakir2, R Frikh2, M Boui2, N Hjira2.   

Abstract

BACKGROUND: The purpose was to study factors associated with the survival of HIV-1 patients receiving antiretroviral therapy in Morocco. MATERIAL AND
METHOD: This was a retrospective study of a cohort of 182 HIV-1 patients receiving antiretroviral therapy in the department of dermatology venereology at the Military Instruction Hospital Mohamed V in Rabat during the period from 1 January 2006 to 1 January 2017. Death of any cause during the study period was considered to be the result of HIV infection. The log-rank test was used to compare the survival curves based on determinants. The Cox regression model analyzed the determinants of survival since induction of antiretroviral therapy.
RESULTS: The median follow-up time was 4.7 years (IQR: 1.97-8.18). The mortality rate was 75 deaths per 1000 person-years. Advanced clinical stage CDC C (RR: 2.72; CI 95%: 1.33-5.56) and treatment with indinavir (RR: 1.41; CI 95%: 0.77-2.59) were significantly associated with death.
CONCLUSION: Initiation of antiretroviral therapy in the early stage of the disease and use of less toxic molecules are recommended to reduce mortality.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Analyse de survie; Antiretroviral therapy; HIV infection; Infection VIH; Survival analysis; Thérapie antirétrovirale

Mesh:

Substances:

Year:  2018        PMID: 30177238     DOI: 10.1016/j.respe.2018.07.001

Source DB:  PubMed          Journal:  Rev Epidemiol Sante Publique        ISSN: 0398-7620            Impact factor:   1.019


  1 in total

1.  [Cost and factors associated with the prescription of non-antiretroviral drugs among HIV-infected patients under antiretroviral therapy in a reference hospital in Morocco].

Authors:  Hicham Titou; Mohammed Boui; Naoufal Hjira
Journal:  Med Trop Sante Int       Date:  2022-01-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.